DEBORAH WEITZMAN - 27 Nov 2023 Form 4 Insider Report for CARDINAL HEALTH INC (CAH)

Role
CEO, Pharmaceutical Segment
Signature
/s/ James E. Barnett, Attorney-in-fact
Issuer symbol
CAH
Transactions as of
27 Nov 2023
Net transactions value
-$1,847,055
Form type
4
Filing time
29 Nov 2023, 09:14:46 UTC
Previous filing
29 Aug 2023
Next filing
05 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CAH Common Shares Options Exercise $504,777 +5,990 +14% $84.27 50,192 27 Nov 2023 Direct F1
transaction CAH Common Shares Options Exercise $522,350 +6,279 +13% $83.19 56,471 27 Nov 2023 Direct F1
transaction CAH Common Shares Options Exercise $1,021,228 +15,373 +27% $66.43 71,844 27 Nov 2023 Direct F1
transaction CAH Common Shares Sale $3,895,411 -36,642 -51% $106.31 35,202 27 Nov 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CAH Employee Stock Option (right to buy) Options Exercise $0 -5,990 -100% $0.000000* 0 27 Nov 2023 Common Shares 5,990 $84.27 Direct F3
transaction CAH Employee Stock Option (right to buy) Options Exercise $0 -6,279 -100% $0.000000* 0 27 Nov 2023 Common Shares 6,279 $83.19 Direct F4
transaction CAH Employee Stock Option (right to buy) Options Exercise $0 -15,373 -100% $0.000000* 0 27 Nov 2023 Common Shares 15,373 $66.43 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 28, 2023.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.11 to $106.76, inclusive. The reporting person undertakes to provide to Cardinal Health, Inc., any security holder of Cardinal Health, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 Stock option vested in three equal installments on August 15, 2016, August 15, 2017, and August 15, 2018.
F4 Stock option vested in three equal installments on August 15, 2017, August 15, 2018, and August 15, 2019.
F5 Stock option vested in three equal installments on August 15, 2018, August 15, 2019, and August 15, 2020.